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Objective:
 
 Breast cancer remains the highest incident
cancer among females in the United States and previous
research suggests that a considerable portion of patients
will eventually progress to the metastatic phase of the
disease. This paper provides the first estimate of the
lifetime direct costs of treating metastatic disease for
one annual diagnostic cohort of breast cancer patients.
 
Methods:
 
 Incidence rates were combined with US popula-
tion counts to estimate the number of breast cancer cases
diagnosed in 1994. Estimates of progression to metastatic
disease (from Canadian provincial cancer registry data),
costs of care (derived from patients’ claims histories), sur-
vival (from SEER data), and national mortality rates
(from US Census Bureau) were integrated, using Statistics
Canada’s Population Health Model (POHEM) to calcu-
late lifetime costs.
 
Results:
 
 This study estimates that more than 40% of
the women diagnosed with breast cancer will progress
to metastatic disease. On average, women with meta-
static disease are expected to live 3 years and to incur
direct treatment costs of approximately $60,000 per
case, resulting in a total lifetime cost for the cohort of
almost $4.2 billion.
 
Conclusions:
 
 The high rate of recurrence of breast cancer
argues for the development of interventions that can pre-
vent or delay the onset of metastatic disease. These esti-
mates of lifetime costs and the methodology on which they
are based can be used to evaluate the cost-effectiveness of
such secondary prevention strategies. These estimates also
can serve as a benchmark against which the lifetime costs
of treating other diseases can be assessed.
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Introduction
 
In 1996, breast cancer was the highest incident
cancer in American females. The 5-year survival
rate is strongly associated with stage at presenta-
tion, varying from 95% for Stage I, 82% for Stage
II, 53% for Stage III, and 19% for Stage IV. Be-
cause more than 85% of women are diagnosed
with either Stage I or II, the overall five-year sur-
vival is quite encouraging, at 80% [1]. However, a
significant portion of the women diagnosed with
primary disease will eventually progress to the
metastatic phase of the disease [2]. The intensity
of care during the metastatic phase of breast can-
cer is quite significant and can be expensive. Con-
sequently, to understand the economic impact of
metastatic breast cancer on the health care system,
and to provide a comparative basis for future
studies on the cost-effectiveness of preventive and
therapeutic interventions, we have estimated the
lifetime direct costs of metastatic breast cancer for
the cohort of women diagnosed with breast cancer
in the United States in 1994.
 
Methods
 
Incidence
 
Incidence rates of breast cancer for 1994 by 5-year
age group and stage were obtained from the Sur-
veillance, Epidemiology and End Results (SEER)
program maintained by the National Cancer Insti-
tute [1]. US female population counts by single
year of age for 1994 were obtained from the US
Bureau of the Census. The number of new cases of
breast cancer diagnosed in 1994 was estimated by
multiplying the SEER incidence rates with the US
population counts.
 
Disease Progression and Survival
 
To estimate the lifetime cost of metastatic breast can-
cer for the cohort of women diagnosed in 1994, it
was necessary to determine: (1) how many women
are initially diagnosed with metastatic disease (avail-
able from SEER), and (2) how many women progress
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to the metastatic phase of the disease at some time
following initial diagnosis. Because data on progres-
sion were not available from SEER, data from pro-
vincial cancer registries in Canada were used to deter-
mine the patterns of breast cancer progression [3–5].
A state transition approach was used with transitions
derived separately for each stage at diagnosis. For
women diagnosed at Stage I, II, or III, the transitions
modeled were: from diagnosis to local recurrence,
from diagnosis to distant recurrence (or metastasis),
or directly from diagnosis to progression and death.
Once there is a local recurrence, transitions to dis-
tant recurrence or to death are possible. Once distant
metastases are found, the only possible transition is
to progressive disease and death. Relative survival for
women with metastatic breast cancer was determined
with the Web-based survival calculator provided at
the SEER Web site (http://www-seer.ims.nci.nih.gov/
ScientificSystems/Canques1973–96), using the cases
initially diagnosed with Stage IV breast cancer be-
tween 1986 and 1993 [6] as being representative of
all patients with metastatic disease. A set of continu-
ous time piece-wise Weibull survival functions was
used to create parameters for state-specific transi-
tions. Figure 1 provides a schematic representation of
disease progression.
 
Resource Utilization and the Direct Costs of Care
 
Data provided by the Clinical Care in America
Data Warehouse (maintained by Protocare Sci-
ences, Reston, VA) were used to characterize care
patterns for patients with metastatic breast cancer.
With ongoing data collection, this database pro-
vided a longitudinal view of health care claims for
more than 4 million covered lives largely concen-
trated in 19 states located in the Southeast and
Midwest [7]. The data included comprehensive
claims histories for patients for the years 1993 to
1997. Within this database, 28,882 female patients
were identified as having breast cancer based on the
existence of an ICD-9-CM Diagnosis code of 174–
174.9 in their claims histories. Among this group,
we selected 344 patients for whom we could deter-
mine the time at which recurrent/metastatic disease
was first detected. Patients’ ages ranged from 30 to
89 years, with a median age of 61 years. More than
40% of patients (44.3%) were less than 60 years of
age, and the remainder were divided evenly, with
28.5% of patients in the 60–70 years age group
and 27.1% over 70 years of age. Determination of
the time of the initial diagnosis of metastatic disease
was accomplished by reliance on an algorithm de-
veloped with the assistance of an expert panel of
oncologists. This algorithm required that the pa-
tient had a biopsy, CT scan (of the chest and/or ab-
domen), and a nuclear scan all performed within a
21-day period. In addition, it was necessary that a
diagnosis of metastatic disease (ICD-9-DM 197.13/
4198.82) occur for the first time in the patient’s his-
tory at the time these tests were performed.
The algorithm used for case selection was vali-
dated through two independent methods. First,
the sample of patients was matched with a group
of patients for whom disease status was known,
because of their inclusion in hospital cancer regis-
tries that recorded stage of disease. The matching
was done with encrypted patient identifiers through
a third party to ensure that patient confidentiality
agreements were respected. Medical Registry Ser-
vices (MRS) (Hackensack, NJ) provided registry
data that included date of recurrence, type of recur-
rence, and TNM and SEER stages for 550 patients
who were also described in the Protocare Sciences
database. Of these patients, MRS classified 41 as
metastatic (with TNM Stage 4, or SEER Stage 7,
at the time of initial diagnosis) or recurrent, and
509 as not having any indication of metastatic or re-
current disease. Our case-finding algorithm yielded
a specificity of 100%, sensitivity of 25%, positive
predictive value of 100% and negative predictive
value of 93%. This analysis suggested that patients
in our analytic set were indeed metastatic or recur-
rent, though many patients with recurrent disease
in the larger database were probably excluded.
As a second check on the accuracy of our algo-
rithm, the treatment history of selected patients in the
year before the estimated recurrence date was exam-
ined to see whether the care they received during that
period was consistent with a disease-free state. Ade-
quate claims histories were available for 54 patients.
Only 4 of these patients had any claims for either
chemotherapy or radiation therapy in the year before
recurrence (one case was likely an extension of pro-
Figure 1 Disease progression.
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longed adjuvant therapy). When contrasted with the
rates of chemotherapy and radiation therapy for this
group of patients in the year following recurrence, it
was clear that the algorithm discriminated between
periods when patients were disease-free and when
they were being treated for recurrent disease.
Because the patients were enrolled in different
health plans, the information on payments was of-
ten not comparable. Further, there is evidence that
reliance on charges can lead to misleading conclu-
sions about actual costs [6]. Therefore, we applied
standard Medicare payments for the services pro-
vided. Hospital admissions were classified into di-
agnosis related groups (DRGs) based on primary
ICD-9 CM diagnosis codes for the admission and
ICD-9 Procedure Codes reported on the hospital
claims. Determination of the appropriate DRG
was facilitated using the IRP Web Medicare DRG/
Calculator (http://www.irpsys.com/cgi-bin/webplus.
exe?Script 
 

 
 /irpsys/drgcalc.wml & calcver 
 

 
medicare) The reimbursement rates for each DRG
were derived from the 1996 MEDPAR Inpatient
Hospital data (http://www.hcfa.gov/stats/medpar/
medpar.htm). The 1998 Fourth Quarter Reim-
bursement Schedule for Durable Medical Equip-
ment and the 1998 National Physician Fee Sched-
ule under the Medicare Program were also obtained
from the Health Care Financing Administration
(HCFA). All professional services were assigned
costs using the relative value units (RVUs) for ser-
vices in the Physician Fee Schedule and multiplying
those RVUs by the 1998-weighting factor of $36.69.
Reimbursements for goods and services covered by
HCFA’s Common Procedural Coding System were
derived from the 1998 Fee Schedule for Empire
Medicare Services (New York, NY), the Medicare
carrier for New York. The costs of prescription
drugs were derived based on the average wholesale
price for those drugs in the April 1998 release of
MediSource
 
TM
 
 Lexicon from Multum Information
Services (http://www.multum.com/Lexicon.htm).
Average costs were calculated on a quarterly
basis for each of the 8 quarters following detec-
tion of recurrence for all categories of cost, except
for drugs. (Eligibility for drug benefits was not
uniform and needed to be determined before drug
costs were examined. In addition, the variability in
spending for drugs within the eligible population
was small. Therefore, this study only examined
drug costs for 4 quarters.) Terminal care costs
were obtained from claims data and included the
sum of all the claims for the last 3 months of life
of those women in the cohort who died. Because
this study measured terminal care costs separately,
only patients who survived more than 90 days past
each quarter were included in the computation of av-
erage costs for that quarter. For women living more
than 2 years, the assumption was that the average
cost observed in the last year of observation would
apply until they either entered the terminal phase of
breast cancer (the last 3 months of life for women dy-
ing of breast cancer), or they died from another
cause. For chemotherapy, claims data was also used
to estimate the time until initiation of treatment and
its duration. The time to initiation of chemotherapy
was constrained to be a maximum of 1 year and the
time on chemotherapy to be a maximum of 3 years.
 
The Population Health Model
 
The Population Health Model (POHEM) is a com-
prehensive microsimulation model that simulates the
health status of a population. The model was devel-
oped by Statistics Canada and is extensively de-
scribed elsewhere [8,9]. It generates and ages over
time, a synthetic cohort of individuals who have
been assigned specific demographic characteristics,
health risk factors, disease onset and progression pa-
rameters, health care resource utilization, and direct
medical care costs. The simulation is performed in
continuous time under a competing risk approach.
The above-mentioned data were incorporated
into POHEM in the following manner: the likeli-
hood that a simulated individual would develop
breast cancer was calculated from the age-specific
incidence rates. POHEM uses random numbers to
generate the outcome for each process it simulates.
Each individual diagnosed with breast cancer in
the simulated population was assigned a stage at
the time of that diagnosis, based on the TNM
stage distribution of breast cancer in the SEER
population [1]. Subsequent progression of the disease
and metastatic breast cancer survival were deter-
mined through the use of piece-wise Weibull survival
functions, in a competing risk framework [3–5].
All costs were determined in constant 1998 US
dollars and the economic analysis was carried out
from the perspective of the payer. Costs were dis-
counted at 0%, 3%, and 5% rates, according to
current convention [10]. To ensure the stability of
the simulation results, a synthetic cohort of 4 mil-
lion women was simulated.
 
Results
 
Incidence, Disease Progression, and Survival
 
We estimated that 161,551 women were diag-
nosed with breast cancer in 1994 (Table 1) and
that 78% of them were aged 50 and over at the
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time of diagnosis. Metastatic breast cancer at pre-
sentation represented only 5% of the cases.
Table 2 provides summary statistics on disease
progression. It is estimated that, on average, women
diagnosed with breast cancer will live 14.5 years. Sur-
vival is strongly associated with the stage at diagno-
sis, varying from a high of 16.9 years for patients di-
agnosed with Stage I disease to a low of 3.2 years for
patients who have Stage IV disease at diagnosis. The
probability of progression to the metastatic phase of
the disease is also strongly associated with stage at
presentation. We estimated that 30, 46, and 71% of
patients initially diagnosed with Stages I, II, and
III disease, respectively, will progress to metastatic
breast cancer. By definition, all Stage IV patients
are assumed to be diagnosed with metastatic breast
cancer. The average durations between the initial di-
agnosis and the progression to metastatic disease
were 10.2, 7.9, and 4.3 years for Stages I, II, and III,
respectively. The lifetime probability of death from
 
Table 1
 
Breast cancer incidence by age group
 
Age Group
 

 
50 50–59 60–69 70–79 80
 

 
All
1994 SEER new cases per 10,000
Stage I 1.4 12.9 19.2 23.9 18.2 5.8
Stage II 1.8 9.3 12.0 13.7 13.1 4.4
Stage III 0.4 1.7 2.0 2.8 3.1 0.9
Stage IV 0.1 1.3 1.9 2.0 2.1 0.6
All 3.7 25.2 35.1 42.5 36.5 11.7
1994 US population
Number in 1000s 95,764 12,473 10,806 8,863 472 128,378
Number of cases diagnosed
Stage I 13,274 16,113 20,763 21,226 9,741 81,117
Stage II 16,981 11,645 12,958 12,155 6,973 60,712
Stage III 3,509 2,108 2,183 2,467 1,651 11,919
Stage IV 1,231 1,588 2,057 1,785 1,142 7,803
All 34,995 31,454 37,960 37,633 19,508 161,551
 
Table 2
 
Disease progression
 
Age at Diagnosis
 

 
50 50–59 60–69 70–79 80
 

 
All
Life expectancy at diagnosis
Stage I 26.6 21.1 15.7 10.9 6.3 16.9
Stage II 21.9 17.4 13.4 9.6 5.5 14.2
Stage III 10.4 9.2 8.0 6.4 4.1 7.9
Stage IV 3.9 3.4 3.3 2.9 2.1 3.1
All 21.9 18.0 13.8 9.8 5.6 14.5
Progression to metastatic disease
Stage I Percent 47 39 31 23 14 32
Mean time 15.1 12.1 9.1 6.7 4.4 9.9
Stage II Percent 61 54 46 38 26 46
Mean time 11.3 8.8 6.9 5.1 3.5 7.4
Stage III Percent 81 78 74 66 51 72
Mean time 5.6 4.9 4.1 3.3 2.4 4.2
Stage IV Percent 100 100 100 100 100 100
Mean time 0.0 0.0 0.0 0.0 0.0 0.0
All Percent 59 50 43 34 27 44
Mean time 11.0 8.8 6.6 4.8 2.8 7.1
Survival of metastatic disease
Stage I Mean time 4.0 3.7 3.3 2.8 2.1 3.1
% dying of BC 97 95 92 86 72 88
Stage II Mean time 4.0 3.6 3.3 2.8 2.1 3.1
% dying of BC 97 95 92 86 72 88
Stage III Mean time 4.0 3.6 3.3 2.9 2.0 3.1
% dying of BC 97 96 92 86 73 88
Stage IV* Mean time 3.9 3.4 3.3 2.9 2.1 3.1
% dying of BC 97 96 92 87 73 88
All Mean time 4.0 3.6 3.3 2.8 2.1 3.1
% dying of BC 97 95 92 86 73 87
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breast cancer is associated with both age and stage at
diagnosis. Women diagnosed at a younger age have a
greater chance of dying from breast cancer simply be-
cause they live longer and are subjected to the risk of
disease progression for a longer time period. It is esti-
mated that mortality due to breast cancer was 59%
for women less than 50 years of age at diagnosis and
39% for women over the age of 50 when their can-
cers are first detected. Disease-associated mortality
varied from a low of 29% (for Stage I) to a high of
89% (for Stage IV).
The all-cause mortality for women with meta-
static breast cancer simulated by POHEM was com-
pared to the all-cause mortality for women in SEER
diagnosed with Stage IV disease between 1986 and
1993. Figure 2 provides a graphical representation
of the two survival curves. From this figure, we can
conclude that the 5-year survival resulting from
POHEM was very close (if not identical) to the
SEER data. This is reassuring, in that POHEM was
used to extend the 5-year survival to lifetime for
women with metastatic breast cancer. The median
survival time for women with metastatic breast can-
cer was estimated to be 17.3 months, while the
mean was 24.7 months. The proportion of women
living more than 5 years was estimated to be 17%.
 
Cost of Care
 
Table 3 provides a summary of the per-patient cost
components derived from the claims data. As that ta-
ble shows, hospitalization was the largest cost com-
ponent for all quarters. The costs of care were highest
for the first quarter and decreased gradually in the
year following detection of metastatic disease. The
costs per-patient-at-risk stabilized in the second year.
Terminal care costs are those costs incurred by the
health care system in the 3 months prior to death
from breast cancer. The terminal care cost was con-
siderable at $13,476 for each woman dying of breast
cancer. Caution should be exercised in using these re-
sults, however, as the confidence intervals are typi-
cally quite large. In most cases they are at least equiv-
alent to the estimates in magnitude and in some cases
(particularly the estimates of costs in quarters more
than a year from disease detection) exceed them by as
much as 50%.
For chemotherapy, this study modeled the time to
chemotherapy and the duration of chemotherapy.
This is why the cost for each woman under treat-
ment rather than the cost for each woman at risk is
reported in Table 3. Chemotherapy was typically ini-
tiated within 2 months of detection of progressive
disease. Figure 3 graphs the duration of therapy for
patients receiving chemotherapy and shows that ap-
proximately 75% of the patients who received che-
motherapy did so for less than a year.
 
Lifetime Costs
 
Of the 161,551 women diagnosed with breast
cancer in 1994, 70,650 of them will eventually
progress to metastatic breast cancer. Table 4 pro-
vides the individual cost components that com-
prise the undiscounted lifetime costs of providing
care to these patients. The total undiscounted life-
time cost of treating metastatic breast cancer was
estimated to be $59,489 a case, resulting in a total
lifetime cost of almost $4.2 billion for the full an-
nual diagnostic cohort. Hospitalization (52.2%),
including professional fees, was the largest ex-
pense category followed by terminal care (17%),
Figure 2 5-year survival of metastatic
cancer patients.
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management and tests (11%), drugs (9%), and ra-
diotherapy (8%). Chemotherapy and hormonal
therapy represented less than 1% each of the life-
time cost. The cost per case decreased with age,
and ranged from a high of $100,493 for women
less than 50 years of age at detection to a low of
$43,143 for women above 80 when disease pro-
gression was first detected. The lifetime costs dis-
counted at 3% and 5% were $3.8 billion and $3.6
billion, respectively, for the full annual diagnostic
cohort.
The lifetime costs were unbundled according to
the number of years since progression to the meta-
static phase of the disease. It is estimated that
43% of the lifetime costs of care were spent in the
first year and that 13, 9, 6, and 5% were spent in
each of the 4 subsequent years. The proportion of
the lifetime costs spent in the first year increase to
48% and 50% when the costs are discounted at a
rate of 3% and 5%, respectively. Importantly, al-
most one-quarter of the costs (24%) are expected
to be spent after the first 5 years.
 
Discussion
 
While others have determined the direct costs of
breast cancer care [11], this study contains the
first estimate of the direct costs incurred by a co-
 
Table 3
 
Two-year costs of care by category
 
Age group Quarter Hospital Costs ($)
Radiotherapy 
($)
Chemotherapy 
($)
Management and tests 
($)
Hormonal therapy 
($)
Drug costs 
($)
 

 
50 1 10,018 1,338 1,681 2,176 25 426
2 6,076 759 1,109 572 13 530
3 3,729 1,424 732 807 17 530
4 1,896 710 822 291 36 317
5 5,667 238 550 493 21 470
6 1,674 49 1,510 273 21 470
7 3,448 96 1,976 426 21 470
8 3,419 627 626 648 21 470
9
 

 
3,784 241 1,023 488 21 470
 

 
50 1 9,945 1,508 934 1,982 43 360
2 2,537 469 1,045 554 52 390
3 1,996 262 975 471 80 467
4 5,851 301 1,022 622 119 559
5 1,324 371 1,281 372 78 458
6 1,283 235 1,493 301 78 458
7 2,186 165 2,487 395 78 458
8 436 570 1,032 258 78 458
9
 

 
1,328 327 1,150 386 78 458
Terminal 
care
Age 
Group
Total
 

 
50 15,807
 

 
50 12,628
Figure 3 Time on chemotherapy.
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hort of patients during the entire metastatic phase
of the disease. The most basic findings, concerning
the total direct per patient and societal costs, are
in line with those previous estimates which placed
the annual direct costs of treating metastatic
breast cancer between $12,262 [12] and $15,847
[13]. Given the projection that patients will live
approximately 4 years from diagnosis of metastatic
disease and recognizing that costs have increased
since the time of these studies (mid-1980s through
early 1990s), the estimates of approximately $60,000
for each patient and $4.2 billion for the full cohort
seem entirely consistent with earlier direct cost esti-
mates. Our contribution therefore is less in develop-
ing the annualized costs than in combining them
with estimates of the probability of recurrence and
the projected length of the metastatic phase.
Perhaps the most striking finding concerns the rel-
atively high rate at which disease recurs. While the
survival rates for breast cancer are impressive com-
pared to other solid tumors, the fact that one-third
of women diagnosed in the earliest stages will have a
recurrence of the disease at some point is a harsh re-
minder of breast cancer’s serious consequences.
It is also interesting to note that the combined
costs of all the available therapeutic modalities
(i.e., chemotherapy, radiation therapy, and hor-
monal therapy) accounted for only about 12% of
total costs. Based on this, it seems that any at-
tempts to diminish the economic consequences of
metastatic breast cancer would be better served by
focusing on hospital or terminal care costs, rather
than on those generated by attempts to extend or
palliate survival.
Our findings that the total cost per patient ap-
proaches $60,000 and that societal costs exceed
$4.1 billion are difficult to evaluate, in the absence
of comparable information on what it costs to
treat the metastatic phase of other cancers or, at a
broader level, what it costs to treat other disease
entities. Our findings create a benchmark against
which to compare estimates of lifetime costs for
other diseases.
Perhaps most importantly, by presenting a
model that integrates incidence and progression,
and creating a model to estimate costs, we have
provided the mechanism through which the cost-
effectiveness of therapies that prevent or delay the
time of onset of metastatic disease in some pa-
tients can be evaluated. As Richards [14] states,
“the cost-effectiveness of measures designed to re-
duce the incidence of advanced cancer can only be
 
Table 4
 
Undiscounted lifetime cost of care for metastatic breast cancer
 
Age Group
Under 50 50 to 59 60 to 69 70 to 79 80 and over All
Number of cases 9,345 12,919 16,192 17,451 14,576 70,483
Costs ($1,000)
Hospital 
 

 
 professional fees 591,173 382,884 453,274 445,161 315,025 2,187,518
Radiotherapy 56,443 71,868 83,645 79,582 53,261 344,798
Chemotherapy 13,170 19,221 23,520 25,330 19,896 101,138
Hormonal therapy 1,630 7,810 9,673 10,020 7,217 36,350
Management and tests 83,960 89,071 104,043 99,689 67,654 444,418
Drug (excluding hormones) 66,591 80,480 91,935 84,272 52,017 375,296
Terminal care 126,144 136,209 163,364 163,977 113,784 703,479
Total 939,112 787,544 908,032 908,032 628,855 4,192,997
Cost ($/person-year)
Hospital 
 

 
 professional fees 15,871 8,225 8,500 9,056 10,300 10,087
Radiotherapy 1,515 1,544 1,569 1,619 1,714 1,590
Chemotherapy 354 413 441 515 650 466
Hormonal therapy 44 168 181 204 236 168
Management and tests 2,254 1,913 1,951 2,028 2,212 2,049
Drug (excluding hormones) 1,788 1,729 1,724 1,714 1,701 1,731
Terminal care 3,387 2,926 3,064 3,336 3,720 3,244
Total 25,212 16,917 17,430 18,473 20,560 19,335
Cost ($/case)
Hospital 
 

 
 professional fees 63,261 29,637 27,993 25,510 21,613 31,036
Radiotherapy 6,040 5,563 5,166 4,560 3,654 4,892
Chemotherapy 1,409 1,488 1,453 1,452 1,365 1,435
Hormonal therapy 174 605 597 574 495 516
Management and tests 8,984 6,895 6,425 5,713 4,642 6,305
Drug (excluding hormones) 7,126 6,230 5,678 4,829 3,569 5,325
Terminal care 13,498 10,543 10,089 9,397 7,806 9,981
Total 100,493 60,959 57,401 52,035 43,143 59,489
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calculated if the cost of treating patients with ad-
vanced disease is accurately known.” This be-
comes particularly pertinent in an era of fiscal re-
straint, in which efficiencies in health care delivery
are being sought. We hope that the result of this
study will help to guide health policy-makers to
make care delivery more efficient and less costly,
by understanding the components of care for met-
astatic breast cancer.
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co-operation, input and comments from numerous indi-
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ada for their collaboration on the use of POHEM. We
also acknowledge the contributions of the Saskatchewan
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